180 related articles for article (PubMed ID: 10232160)
1. A review of paclitaxel (Taxol) administration, stability, and compatibility issues.
Boyle DA; Goldspiel BR
Clin J Oncol Nurs; 1998 Oct; 2(4):141-5. PubMed ID: 10232160
[TBL] [Abstract][Full Text] [Related]
2. Physical and chemical stability of paclitaxel infusions in different container types.
Donyai P; Sewell GJ
J Oncol Pharm Pract; 2006 Dec; 12(4):211-22. PubMed ID: 17156593
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical properties of paclitaxel and their effects on preparation and administration.
Trissel LA
Pharmacotherapy; 1997; 17(5 Pt 2):133S-139S. PubMed ID: 9322880
[TBL] [Abstract][Full Text] [Related]
4. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Trissel LA; Bready BB
Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of paclitaxel-containing liposomes.
Holvoet C; Vander Heyden Y; Lories G; Plaizier-Vercammen J
Pharmazie; 2007 Feb; 62(2):126-32. PubMed ID: 17341033
[TBL] [Abstract][Full Text] [Related]
6. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
7. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Trissel LA; Martinez JF
Am J Hosp Pharm; 1993 Feb; 50(2):300-4. PubMed ID: 8097617
[No Abstract] [Full Text] [Related]
8. Seventy-two-hour stability of Taxol in 5% dextrose or 0.9% sodium chloride in Viaflo, Freeflex, Ecoflac and Macoflex N non-PVC bags.
Pourroy B; Botta C; Solas C; Lacarelle B; Braguer D
J Clin Pharm Ther; 2005 Oct; 30(5):455-8. PubMed ID: 16164492
[TBL] [Abstract][Full Text] [Related]
9. Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
Adams JD; Flora KP; Goldspiel BR; Wilson JW; Arbuck SG; Finley R
J Natl Cancer Inst Monogr; 1993; (15):141-7. PubMed ID: 7912520
[TBL] [Abstract][Full Text] [Related]
10. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
Sparreboom A; Baker SD; Verweij J
J Clin Oncol; 2005 Nov; 23(31):7765-7. PubMed ID: 16258080
[No Abstract] [Full Text] [Related]
13. Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Drug Dev Ind Pharm; 2011 Jun; 37(6):628-37. PubMed ID: 21401339
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical issues: preparation, administration, stability, and compatibility with other medications.
Goldspiel BR
Ann Pharmacother; 1994 May; 28(5 Suppl):S23-6. PubMed ID: 7915155
[TBL] [Abstract][Full Text] [Related]
16. Effect of unpurified Cremophor EL on the solution stability of paclitaxel.
Gogate US; Schwartz PA; Agharkar SN
Pharm Dev Technol; 2009; 14(1):1-8. PubMed ID: 18791935
[TBL] [Abstract][Full Text] [Related]
17. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
[TBL] [Abstract][Full Text] [Related]
18. Avoiding carcinogen exposure with intraperitoneal paclitaxel.
Stuart OA; Knight C; Sugarbaker PH
Oncol Nurs Forum; 2005 Jan; 32(1):44-8. PubMed ID: 15660142
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
Hureaux J; Lagarce F; Gagnadoux F; Vecellio L; Clavreul A; Roger E; Kempf M; Racineux JL; Diot P; Benoit JP; Urban T
Eur J Pharm Biopharm; 2009 Oct; 73(2):239-46. PubMed ID: 19560538
[TBL] [Abstract][Full Text] [Related]
20. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics.
Nornoo AO; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):117-23. PubMed ID: 17869458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
